Nexalin Technology (NXL) Income from Continuing Operations (2021 - 2026)
Nexalin Technology (NXL) posted quarterly Income from Continuing Operations of 2096837.0 for Q1 2026, down 5.51% year-over-year from 2219167.13 in Q1 2025, and up 11.77% quarter-over-quarter from 2376546.0 in Q4 2025.
Nexalin Technology (NXL) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Nexalin Technology's Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 2096837.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 5.51% year-over-year to 2096837.0; the TTM figure through Mar 2026 stood at 8330681.0 (up 2.54% YoY), while the FY2025 annual figure was 6495133.0, up 14.62% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 2096837.0, up from 2376546.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 303646.0 in Q3 2022, with the low at 2828624.0 in Q4 2024.
- The 5-year median for Income from Continuing Operations is 1283202.0 (2024), against an average of 1439969.18.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations soared 83.34% in 2022, then sank 656.54% in 2023.
- Nexalin Technology's Income from Continuing Operations stood at 758617.0 in 2022, then slipped by 2.91% to 780669.0 in 2023, then tumbled by 262.33% to 2828624.0 in 2024, then gained by 15.98% to 2376546.0 in 2025, then advanced by 11.77% to 2096837.0 in 2026.
- Business Quant data shows NXL's Income from Continuing Operations at 2096837.0 in Q1 2026, 2376546.0 in Q4 2025, and 2276311.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.50 Bn | 194.89 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 130.00 Bn | 126.52 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 120.36 Bn | 111.14 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 74.19 Bn | 73.65 Bn | 3.85 Bn | 905.00 Mn |
| 5 | Edwards Lifesciences | 52.73 Bn | 48.48 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.64 Bn | 32.70 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 34.13 Bn | 32.02 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.52 Bn | 23.20 Bn | 4.55 Bn | 1.04 Bn |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Nexalin Technology | 7.11 Mn | 6.11 Mn | 8,897.00 | -2.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.24 Mn |
| Mar 31, 2026 | -2.10 Mn |
| Dec 31, 2025 | -2.38 Mn |
| Sep 30, 2025 | -2.28 Mn |
| Jun 30, 2025 | -1.58 Mn |
| Mar 31, 2025 | -1.99 Mn |
| Dec 31, 2024 | -2.83 Mn |
| Sep 30, 2024 | -2.45 Mn |
| Jun 30, 2024 | -1.28 Mn |
| Mar 31, 2024 | -1.05 Mn |
| Dec 31, 2023 | -780,669.00 |
| Sep 30, 2023 | -2.30 Mn |
| Jun 30, 2023 | -822,437.00 |
| Mar 31, 2023 | -748,414.00 |
| Dec 31, 2022 | -758,617.00 |
| Sep 30, 2022 | -303,646.00 |
| Jun 30, 2022 | -450,103.00 |
| Mar 31, 2022 | -393,249.00 |
| Dec 31, 2021 | -595,928.00 |
| Sep 30, 2021 | -1.82 Mn |